Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BCRX

BCRX - BioCryst Pharmaceuticals Inc Stock Price, Fair Value and News

$6.65-0.11 (-1.63%)
Market Closed

79/100

BCRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

79/100

BCRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$10.19

Target 3M

$7.63

Target 6M

$8.58

BCRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCRX Price Action

Last 7 days

-1.0%

Last 30 days

-13.8%

Last 90 days

-8.3%

Trailing 12 Months

-16.1%

BCRX RSI Chart

BCRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCRX Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-159.48

Price/Sales (Trailing)

2.33

EV/EBITDA

54.69

Price/Free Cashflow

27.89

BCRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$10.19

Target 3M

$7.63

Target 6M

$8.58

BCRX Fundamentals

BCRX Revenue

Revenue (TTM)

599.8M

Rev. Growth (Yr)

36.14%

Rev. Growth (Qtr)

-2.42%

BCRX Earnings

Earnings (TTM)

-8.8M

Earnings Growth (Yr)

191.92%

Earnings Growth (Qtr)

153.67%

BCRX Profitability

EBT Margin

-1.10%

Return on Equity

2.26%

Return on Assets

-1.97%

Free Cashflow Yield

3.59%

BCRX Investor Care

Shares Dilution (1Y)

1.65%

Diluted EPS (TTM)

-0.05

BCRX Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025503.5M557.5M599.8M0
2024355.4M382.2M412.6M450.7M
2023289.7M306.6M317.6M331.4M
2022188.0M203.6M238.4M270.8M
202132.0M79.1M114.0M157.2M
202047.8M49.2M53.5M17.8M
201922.6M11.5M11.8M48.8M
201819.7M29.1M21.8M20.7M
201731.0M29.3M30.3M25.2M
201646.3M25.2M22.0M26.4M
201517.0M41.4M49.1M48.3M
201417.2M17.9M18.7M13.6M
201317.6M14.2M10.9M17.3M
201226.4M26.9M27.4M26.3M
201141.7M37.9M31.1M19.6M
201000062.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About BioCryst Pharmaceuticals Inc

BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEbiocryst.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES531

BioCryst Pharmaceuticals Inc Frequently Asked Questions

BCRX is the stock ticker symbol of BioCryst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of BioCryst Pharmaceuticals Inc is 1.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BCRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether BCRX is over valued or under valued. Whether BioCryst Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact BioCryst Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCRX.

As of Wed Jan 28 2026, BCRX's PE ratio (Price to Earnings) is -159.48 and Price to Sales (PS) ratio is 2.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, BioCryst Pharmaceuticals Inc has provided -0.005 (multiply by 100 for percentage) rate of return.